Barbara Zalewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Barbara Zalewska has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Przemysław Zalewski
Department of Pharmacognosy and Biomaterials, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland
2 shared publications - Antoni Staniewski
Student Research Group of Cardiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
1 shared publication - Joanna Maćkowiak
Student Research Group of Cardiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
1 shared publication - Judyta Cielecka-Piontek
Department of Pharmacognosy and Biomaterials, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland
1 shared publication - Julia Gierszewska
Student Research Group, Medical Faculty, Poznan University of Medical Sciences, 61-107 Poznan, Poland
1 shared publication - Katarzyna Zalewska
Student Research Group of Cardiology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
1 shared publication
Latest Publications
- Open Access
Phytonutrients in Diseases of Affluence: Advances, Mechanisms, and Therapeutic Perspectives
Diseases of affluence, including obesity, type 2 diabetes mellitus, cardiovascular diseases, metabolic dysfunction-associated steatotic liver disease (MASLD), inflammatory bowel diseases, and selected cancers, represent some of the most significant public health challenges worldwide
Open AccessPhytonutrients in Diseases of Affluence: Advances, Mechanisms, and Therapeutic Perspectives
Diseases of affluence, including obesity, type 2 diabetes mellitus, cardiovascular diseases, metabolic dysfunction-associated steatotic liver disease (MASLD), inflammatory bowel diseases, and selected cancers, represent some of the most significant public health challenges worldwide
- Top Cited PapersOpen Access
Chlorogenic Acid’s Role in Metabolic Health: Mechanisms and Therapeutic Potential
Chlorogenic acid (CGA), an ester of caffeic and quinic acids, is a dietary polyphenol abundant in coffee, tea, fruits, vegetables, and medicinal plants, with 5-O-caffeoylquinic acid (5-CQA) as its predominant isomer. This review aims to summarize current knowledge on the biological activities, mechanisms of action, and potential therapeutic applications of CGA in the prevention and management of metabolic disorders. CGA demonstrates a broad spectrum of biological activities relevant to human health. Its mechanisms of action involve modulation of oxidative stress and key cellular signaling pathways, as well as regulation of metabolic processes, contributing to improved insulin sensitivity, lipid balance, and overall energy homeostasis. These properties make CGA a promising agent against metabolic syndrome (type 2 diabetes, obesity, hypertension, and dyslipidemia) which is a major global health challenge. Despite its health benefits, CGA’s oral bioavailability remains limited, prompting research into optimized extraction methods, novel formulations, and structural modifications. Current evidence supports its safety even at high doses, reinforcing its potential as a nutraceutical, functional food ingredient, and adjunctive therapeutic compound in chronic disease management.
Top Cited PapersOpen AccessChlorogenic Acid’s Role in Metabolic Health: Mechanisms and Therapeutic Potential
Chlorogenic acid (CGA), an ester of caffeic and quinic acids, is a dietary polyphenol abundant in coffee, tea, fruits, vegetables, and medicinal plants, with 5-O-caffeoylquinic acid (5-CQA) as its predominant isomer. This review aims to summarize current knowledge on the biological activities, mechanisms of action, and potential therapeutic applications of CGA in the prevention and management of metabolic disorders. CGA demonstrates a broad spectrum of biological activities relevant to human health. Its mechanisms of action involve modulation of oxidative stress and key cellular signaling pathways, as well as regulation of metabolic processes, contributing to improved insulin sensitivity, lipid balance, and overall energy homeostasis. These properties make CGA a promising agent against metabolic syndrome (type 2 diabetes, obesity, hypertension, and dyslipidemia) which is a major global health challenge. Despite its health benefits, CGA’s oral bioavailability remains limited, prompting research into optimized extraction methods, novel formulations, and structural modifications. Current evidence supports its safety even at high doses, reinforcing its potential as a nutraceutical, functional food ingredient, and adjunctive therapeutic compound in chronic disease management.